AbCellera Biologics Inc.
AbCellera is a clinical-stage biotechnology company that discovers and develops antibody medicines for patients, focusing on indications with high unmet medical need. Its integrated platform combines antibody discovery, engineering, data and computational tools, and clinical manufacturing to advance programs from target selection toward clinical trials. AbCellera is developing its own pipeline, including ABCL635 for menopausal vasomotor symptoms, ABCL575 for atopic dermatitis and other inflammatory conditions, and development candidates for autoimmunity and oncology. It also works with pharmaceutical and biotechnology companies on antibody discovery programs. AbCellera earns near-term payments for partner access, research and intellectual property rights, as well as milestone payments and royalties on drug sales; some agreements also include equity or co-investment options. Its clinical manufacturing facility is in Vancouver, where the company is headquartered.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ABCL in the last 7 days.
No SEC Form 4 filings for $ABCL in the last 30 days.
See all $ABCL insider activity →Jefferies initiated coverage on AbCellera (NASDAQ:ABCL) with a buy rating and $21 target, citing its antibody platform and clinical pipeline. The stock has surged 282% YTD. Other analysts have mixed ratings and targets. AbCellera recently announced a $200M stock offering. The company develops antibody therapies.
U.S. analyst updates on October 12th, 2026, show a cautious outlook with more price-target reductions than increases. Financials, insurance, and real estate saw conservative valuations, while tech sentiment was mixed. Energy received stronger support, and healthcare saw positive coverage.
UBS initiates coverage of AbCellera Biologics with a Buy rating and a $18 price target. The stock is currently trading at $12.54, up 4.37% in pre-market. The rating is based on valuation, EPS revisions, and visibility metrics.
Recent ABCL coverage spans financial news, market movers and technology.
Street initiation is a fresh sentiment catalyst, but the article is largely analyst framing around already-known pipeline progress.
New coverage with a Buy and defined target can attract incremental attention and flows.
UBS initiates coverage of AbCellera Biologics with a Buy rating and a $18 price target. The stock is currently trading at $12.54, up 4.37% in pre-market. The rating is based on valuation, EPS revisions, and visibility metrics.
The announcement signals upcoming clinical data that could move the stock once released.
Positive Phase‑2 results could lift the stock.
AlphAI scores every news story that mentions ABCL with an AI model for sentiment and relevance, and aggregates insider trades from AbCellera Biologics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jefferies initiated coverage on AbCellera (NASDAQ:ABCL) with a buy rating and $21 target, citing its antibody platform and clinical pipeline. The stock has surged 282% YTD. Other analysts have mixed ratings and targets. AbCellera recently announced a $200M stock offering. The company develops antibody therapies.
U.S. analyst updates on October 12th, 2026, show a cautious outlook with more price-target reductions than increases. Financials, insurance, and real estate saw conservative valuations, while tech sentiment was mixed. Energy received stronger support, and healthcare saw positive coverage.
UBS initiates coverage of AbCellera Biologics with a Buy rating and a $18 price target. The stock is currently trading at $12.54, up 4.37% in pre-market. The rating is based on valuation, EPS revisions, and visibility metrics.
AbCellera (ABCL) will present Phase 1/2 data for ABCL635, a non-hormonal treatment for menopausal vasomotor symptoms, at The Menopause Society’s 2026 Annual Meeting. The data includes safety, pharmacokinetics, and efficacy results from ongoing trials. ABCL635 targets NK3R, a protein involved in body temperature regulation.
Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.
Iovance (IOVA) surged 31% to a 2-year high after raising its 2026 revenue outlook to $410M-$420M, exceeding consensus. AbCellera (ABCL) gained 6% with JPMorgan initiating coverage with an 'Overweight' rating and $17 target. CrowdStrike (CRWD) rose 1% after announcing plans to integrate with OpenAI's marketplace. Retail sentiment improved for IOVA and ABCL but remained bearish for CRWD.
U.S. stock futures were flat on Tuesday. Summit Therapeutics (SUM) rose 17.1% after AstraZeneca's $2B investment. Fair Isaac (FICO) fell 15% due to FHFA mortgage pricing changes. CarMax (KMX) gained 3.7% on strong Q2 earnings. AAR Corp. (AIR) surged 6.9% after a $4B acquisition and earnings beat. Netflix (NFLX) rose 1.4% after a Deutsche Bank upgrade.
Abcellera Biologics (ABCL) stock rose 2.1% pre-market after JPMorgan initiated coverage with an Overweight rating and $17 price target, citing confidence in its clinical-stage pipeline. The stock has gained over 400% in a year, driven by strong Phase 2 data for its menopause drug, ABCL635. Analysts broadly see upside from current levels, with a consensus price target above $14.23.
JPMorgan initiated coverage of AbCellera Biologics with an 'Overweight' rating and a $17 price target, according to the company. The stock was trading at $13.92 in pre-market, up 9.61% on the day.
Goldman Sachs resumed coverage of AbCellera Biologics (NASDAQ:ABCL) with a Neutral rating and a $13.00 price target. The company reported Q2 revenue of $4.1M, missing estimates, but announced successful Phase 2 trial results for ABCL635, leading Truist to raise its price target to $30. AbCellera has a strong cash position and recently launched a $200M stock offering.
